Articles tagged with Type 2 Diabetes
A study presented at ENDO 2026 found semaglutide was associated with a 15% reduction in bone fractures and greater weight loss compared to other anti-obesity medications. The results suggest that semaglutide may have beneficial effects on bone health in people with type 2 diabetes.
A study found that testosterone alone is not enough to prevent type 2 diabetes in older men; lifestyle interventions are crucial for improving blood sugar control and reducing obesity. Testosterone treatment can improve body composition and sexual desire, but its benefits diminish over time.
Researchers at Sanford Burnham Prebys Medical Discovery Institute found that enhancing protein-folding processes can help prevent harm to insulin-producing cells. The study revealed the importance of a chaperone protein called binding immunoglobulin protein and its cochaperone protein p58 IPK in maintaining proper proinsulin folding.
A reduction in visceral fat is associated with better cardiometabolic health and lower future type 2 diabetes risk, even when body weight is fully regained. Visceral fat loss achieves a significant protective effect against systemic aging and metabolic decay long after a diet ends.
Researchers at UVA are testing the SIPsmarter program to reduce sugary drink consumption among children and their parents. The study aims to improve beverage quality and overall health outcomes in rural areas with high rates of sugary drink consumption.
Persons with diabetes are at higher risk of periodontitis, tooth loss, and peri-implantitis. Poor blood sugar control exacerbates these risks, highlighting the importance of close collaboration between healthcare and dental care providers.
A new oral GLP-1 medication, elecoglipron, has been shown to significantly reduce blood glucose levels and bodyweight in adults with type 2 diabetes. The study found that up to 89.6% of participants achieved an HbA1c level of 7%, while 72.3% experienced at least 5% weight reduction.
Researchers found dapagliflozin significantly reduces risk of heart failure hospitalization in individuals carrying a cardiomyopathy genetic variant. The study, published in Nature Medicine, highlights the potential for incorporating genetic screening into heart failure prevention strategies.
A study analyzing insurance claims data found similar risks between continued and non-continued GLP-1RA medication use during early pregnancy. The authors conclude that further research is needed to better understand the safety of GLP-1RAs in pregnancy due to imprecise estimates for rare outcomes.
A new study found that U.S. military veterans with both insomnia and obstructive sleep apnea have a substantially elevated risk of developing type 2 diabetes compared to those with either condition alone. The risk is particularly high among younger veterans, even after accounting for demographic and metabolic factors.
A study of over 229,000 obese adults without diabetes found that weight loss drugs, such as semaglutide and tirzepatide, were associated with a 41% decrease in the overall risk of developing obesity-related cancers. GLP-1 RAs also showed larger reductions in certain subgroups, including men and gynaecologic cancers.
A study found that adding orfglipron to titrated insulin glargine significantly improved glycemic control and body weight in participants with type 2 diabetes. The treatment did not increase the risk of hypoglycemia, compared to placebo.
A major study finds people with diabetes are at higher risk of infection, which can lead to hospitalization and death. The researchers argue that infection prevention and management should be embedded in diabetes guidelines to improve patient outcomes.
Recent studies show finerenone preserves kidney function, reduces cardiovascular risk and improves survival across a broader range of CKD patients. Finerenone also reduces kidney failure, heart failure or cardiovascular death risk by 23-24% in non-diabetic patients.
A new study found that dihydropyridine calcium-channel blockers (DCCBs) may be associated with poorer kidney outcomes in people with type 2 diabetes, even among those receiving modern kidney-protective treatments. DCCBs were linked to a higher risk of major adverse kidney events.
The FLOW trial shows that semaglutide significantly improved health-related quality of life in adults with type 2 diabetes and chronic kidney disease. Health utility scores and self-rated general health scores improved with semaglutide, but declined with placebo.
The study found that participants in the 'Healthy Living' online program experienced moderate improvements in their blood sugar levels, blood pressure, and body mass index (BMI). The program was designed to support self-management of type 2 diabetes and showed promising results in England.
Researchers from Pennington Biomedical will showcase their latest findings on prevention, care, and cures for diabetes and obesity at the American Diabetes Association's 2026 Scientific Sessions. The sessions will highlight cutting-edge advancements driving progress in diabetes research and management.
A new study reveals how Philip Morris Companies Inc. used cigarette research and flavor engineering to design Lunchables, a successful ultra-processed food for children. The company's strategy was based on optimizing 'technical synergies' between tobacco and food divisions.
A new model predicts retinal degeneration in diabetics based on 71 plasma proteins. The Pro-DRN model can help doctors identify patients at risk earlier, potentially preventing neurodegeneration and vision loss.
Weight loss after bariatric surgery is associated with better ability to cope with daily household tasks such as cleaning and grocery shopping. The study also found that maintaining weight loss for long periods results in improved functionality and independence. Patients who regained lost weight experienced poorer outcomes over time.
A nationally representative study found a nearly 4-fold increase in type 2 diabetes prevalence among US children and adolescents between 10 to 17 years old. The substantial rise is concerning due to the disease's lifetime risk of severe complications and premature deaths.
Research finds gestational diabetes significantly increases risk of type 2 diabetes in women with normal pre-pregnancy weight. The study, published in eClinicalMedicine, analyzed over 1.15 million Swedish mothers and found elevated blood sugar levels predict future type 2 diabetes.
A new study by UMass Amherst researchers found that lifestyle factors such as body weight, physical activity, and diet play a powerful role in shaping diabetes risk. More than half of new Type 2 diabetes cases could be prevented if people with less healthy lifestyles improve those behaviors.
Researchers are developing a multi-organ model on a chip to study the complex interactions between organs, hormones, and cells in diabetes and dementia. The GlucoBrain project aims to understand how signals move between the brain, gut, and pancreas, potentially leading to new treatments for millions affected by these diseases.
Researchers have identified potential mechanisms linked to reduced type 2 diabetes risk in chronic cannabis users. A team led by Nicholas V. DiPatrizio found that specific compounds within cannabis regulate metabolism, leading to significant weight loss and improved glucose regulation in obese mice.
A new international study found that genetic variations in the PAM gene can reduce the effectiveness of GLP-1 receptor medications, such as Ozempic. Researchers discovered that 44% of people with these genetic variants experienced reduced glucose lowering properties, and only 11% achieved recommended glucose levels.
A $10 million grant from the National Institute of Environmental Health Sciences will support research on PFAS health effects and translate discoveries into real-world solutions. The study aims to identify links between PFAS exposure and metabolic conditions, such as obesity and type 2 diabetes.
Researchers at Kyoto University discovered that ATF6α plays a critical role in enabling the survival and proliferation of beta cells under sustained stress, leading to impaired beta cell mass expansion. The study highlights the potential for developing new therapeutic strategies to preserve and restore beta cell mass in diabetes.
A new review found that GLP-1 weight-loss drugs significantly reduced the risk of heart attacks, strokes, and premature death. The treatment also lowered rates of non-fatal heart attacks, hospital admissions for heart failure, and deaths from any cause.
A new approach for treating obesity and type 2 diabetes has been developed using a hybrid molecule that targets specific cells. The treatment combines the well-known GLP-1/GIP signalling pathway with an additional metabolic modulator, delivering improved blood-glucose values and weight loss.
Researchers mapped epigenome changes in cells that regulate blood sugar levels, finding patterns differ between people with and without type 2 diabetes. Epigenetic alterations impact insulin-producing beta cells, leading to impaired energy production and reduced insulin release.
A study of 3,000 Punjabi Sikhs identified new molecular pathways contributing to cardiovascular disease, including a link between lipid metabolites and immune cell signaling. These findings offer insights into diverse molecular origins of cardiometabolic disease and potential pathways for designing innovative therapies.
The European Society of Endocrinology organizes World Hormone Day to educate the public about hormone-related health issues. Global endocrine disorders affect millions worldwide, emphasizing the need for proper hormone balance.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 32% of the US adult population. Obesity was identified as the strongest independent MRF among Asians, Whites, and Hispanics, particularly in individuals younger than 50 years, whereas hypertension was the strongest independent MRF in Blacks.
A major clinical trial found that real-time continuous glucose monitoring significantly improves blood glucose management in adults with type 2 diabetes treated with basal insulin. Participants using CGM showed greater reductions in HbA1c levels compared to traditional finger prick glucose monitoring.
A ketogenic diet has been shown to improve beta-cell function in patients with type 2 diabetes by decreasing proinsulin secretion and reducing pancreas stress. This improvement is associated with changes in the proinsulin-C-peptide ratio, a biomarker of pancreas stress.
A recent study from The Jackson Laboratory has identified dozens of unexpected genes strongly linked to type 2 diabetes. These genes are key to cell death and vitamin A metabolism, suggesting the disease depends on expression changes that can be targeted for treatment.
A massive genetic study has uncovered six new genes linked to pregnancy sickness, hyperemesis gravidarum (HG), in over 10,000 women. The findings point to biological mechanisms behind HG and potential new treatment pathways, with several medications identified as potential targets.
A new study by Stanford Medicine scientists has identified a genetic variant that causes resistance to GLP-1 diabetes drugs in up to 10% of the population. The variant affects an enzyme called PAM, which handicaps the hormone's biological activity, leading to increased levels but reduced effectiveness.
A study of over 600,000 people found that early weight gain is associated with a higher risk of dying from various diseases, particularly cardiovascular disease and type 2 diabetes. Weight gain during adulthood also increases the risk of premature death, especially for those who develop obesity at a younger age.
A new study uses an AI model to predict type 2 diabetes risk based on behavioral and psychosocial information. The digital twin model found that loneliness, insomnia, and poor mental health substantially raise a person's future risk of developing the disease.
Research published in Ethnicity & Disease found that self-employed Hispanic women report less high blood pressure, obesity, and poor health compared to their salaried counterparts. They were also more likely to exercise, with a nearly 11% higher rate of physical activity.
A preclinical study found that short-term high-fat diet exposure rapidly depletes critical gut immune cells called ILC3s, leading to intestinal permeability and inflammation. The loss of these cells compromises intestinal barrier function and may contribute to chronic diseases linked to inflammation.
A $35 monthly insulin out-of-pocket cap is associated with significantly lower insulin costs, increased access to insulin, and decreased blood glucose levels among Medicare beneficiaries. This finding suggests that federal cost-sharing policies could improve access to essential medications in diabetes.
A lower semaglutide price could generate savings that offset the cost of treating an additional 550,000 to 3.6 million Medicare beneficiaries eligible for expanded obesity-indication coverage. This voluntary price agreement may lead to substantial savings for Medicare spending on semaglutide treatment.
A new study found that adults with obstructive sleep apnea have a 71% higher risk of cardiovascular events or death from any cause compared to those without the condition. People with OSA also experience higher rates of obesity, diabetes, osteoarthritis, anxiety, and depression.
A team from SickKids discovered a therapeutic target in fat tissue that improves cellular function and reduces inflammation. Low-dose homoharringtonine treatment selectively eliminates senescent cells, improving metabolic problems and preserving lean mass.
Researchers found a clear connection between oral health and kidney health, with immune dysregulation and systemic inflammation driving the relationship. The study highlights the need for physicians to integrate oral and renal health into clinical care systems.
Researchers found that adults with type 2 diabetes who switched from dulaglutide to tirzepatide reported improved emotional responses and a greater quality of life. The study suggests that tirzepatide may offer broader benefits beyond glucose control, improving patients' physical and emotional well-being.
A study by IBEC reveals how thousands of amylin mutations influence its tendency to form toxic aggregates in the pancreas, linked to type 2 diabetes. The researchers created a mutational map using deep mutational scanning, identifying variations that promote or hinder amyloid formation.
A review highlights the importance of healthy lifestyles in reducing the risk of cardiovascular disease and type 2 diabetes. Adhering to optimal lifestyle factors, such as a heart-healthy diet, regular physical activity, and adequate sleep, can dramatically lower disease incidence.
The Endocrine Society supports the INSULIN Act to address insulin affordability, setting a $35 monthly cap for people with private insurance and creating a program for uninsured individuals. The bill aims to reduce insulin prices by encouraging competition in the market.